


## Cabotegravir-d<sub>5</sub>

Cat. No.:	HY-15592S1
CAS No.:	2750534-77-9
Molecular Formula:	C <sub>19</sub> H <sub>12</sub> D <sub>5</sub> F <sub>2</sub> N <sub>3</sub> O <sub>5</sub>
Molecular Weight:	410.38
Target:	HIV Integrase; HIV; Isotope-Labeled Compounds
Pathway:	Metabolic Enzyme/Protease; Anti-infection; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Cabotegravir-d <sub>5</sub> is deuterium labeled Cabotegravir.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. *Xenobiotica*. 2015 Jul 1:1-16.
- [3]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. *Xenobiotica*. 2015 Sep 4:1-12.
- [4]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. *Xenobiotica*. 2015 Sep 4:1-12.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA